PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.70
0.00 (0.00%)
At close: 2:46PM EDT
Stock chart is not supported by your current browser
Previous Close0.70
Open0.74
Bid0.70 x 0
Ask0.72 x 0
Day's Range0.65 - 0.74
52 Week Range0.50 - 24.00
Volume9,411
Avg. Volume115,226
Market CapN/A
Beta1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-03-08
1y Target EstN/A
  • CNW Group6 days ago

    Canntab Engages Industry Leader Lorne Gertner as Consultant

    TORONTO, July 16, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that it has engaged Lorne Gertner, one of the world's foremost investors in the cannabis industry and one of its trailblazing pioneers, as a strategic consultant.  Mr. Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding of retail distribution, both of which Canntab hopes to leverage as it positions itself for expansion into international markets. Mr. Gertner is a serial entrepreneur with experience in start-ups, IPOs, fashion, retail, architecture, real estate, and finance.

  • Newsfile11 days ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI with FSD Pharma to Obtain License to Process and Sell Cannabis Based Products - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - Canntab Therapeutics (CSE: PILL), a cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has entered into a non-binding letter of intent with FSD Pharma Inc. (CSE:HUGE). FSD Pharma, through its wholly-owned subsidiary FV Pharma, is a licensed producer under the Access to Cannabis for Medical Purposes Regulations.InvestmentPitch Media has produced a "video" which provides ...

  • CNW Group13 days ago

    Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms

    TORONTO, July 9, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab"), a leader in the rapidly growing cannabis pill market, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with FSD Pharma Inc. (CSE:HUGE) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction"). FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the "Canntab Premises").

  • Canntab Announces Launch of Innovative Hemp Oil Capsules
    Newsfilelast month

    Canntab Announces Launch of Innovative Hemp Oil Capsules

    Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the Health Canada approval and launch of the first of its '420 Therapeutics' brand of Cannabis wellness products: Hemp Oil Gel Capsules. Made from purified organic hemp seed oil, the Hemp Oil Gel Capsules are an easy and convenient way to enjoy the health benefits of hemp oil.Each Hemp Oil Gel Capsule contains ...

  • Newsfilelast month

    Canntab Announces Director Resignation

    Toronto, Ontario--(Newsfile Corp. - June 14, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") announces that Sheldon Inwentash has resigned from the Company's Board of Directors to pursue other opportunities. Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, "I would like to thank Sheldon for his valuable contributions to the Company and, on behalf of the Board, I wish him every success in his future endeavours."About CanntabCanntab Therapeutics Limited is ...

  • GlobeNewswire2 months ago

    Canntab: Advancing Cannabinoid Research in Australia -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Canntab Therapeutics Ltd. (PILL.CN) (PILL.CN) (PILL.CN) and its Canntab XR cannabinoid tablets that offer pharmaceutical-grade formulation to help doctors and patients control their dosing, as well as help researchers better study the drug in clinical trials. The company is pioneering this work in a new Australian joint venture that investors may want to note when looking for investment opportunities in the medical space. Many countries are starting to recognize the medical benefits of cannabis.

  • GlobeNewswire2 months ago

    CORRECTING and REPLACING – Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media

    In a release issued yesterday under the same headline by CFN Media, please be advised that a quote has been removed from the first paragraph. Additionally, the stock exchange for Emblem Corp. in the ninth paragraph should be TSX-V rather CSE, and the reference in that same paragraph to "five projects" should simply read "projects". The corrected release follows. CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering CannTab Therapeutics Inc. (PILL.CN) (PILL.CN) (PILL.CN) and its plan to make medical cannabis more reliable with its proprietary, patent-pending, extended-release tablets that offer a reliable and uniform dosage over several hours.

  • GlobeNewswire2 months ago

    Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering CannTab Therapeutics Inc. (PILL.CN) (PILL.CN) (PILL.CN) and its plan to make medical cannabis more reliable with its proprietary, patent-pending, extended-release tablets that offer a reliable and uniform dosage over several hours. By making medical cannabis more like traditional pharmaceuticals, these products should be more readily prescribed by doctors than the smoking of cannabis flower. Dr. Andrew Weil, director of integrative medicine at the University of Arizona College of Medicine states, “As a physician, I am frustrated that I cannot prescribe marijuana for patients who might benefit from it.

  • Newsfile2 months ago

    Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis

    Toronto, Ontario--(Newsfile Corp. - May 25, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 2 additional Canadian patent applications. Canntab's portfolio now includes 13 patent applications in Canada, the United States and internationally. These filings build on Canntab's growing intellectual property portfolio, which already included patent applications and ...

  • Newsfile2 months ago

    Canntab Appoints Bob Woloschuk to Advisory Board

    Toronto, Ontario--(Newsfile Corp. - May 17, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the appointment of Bob Woloschuk to its Advisory Board. Bob has over 20 years of pharmaceutical executive experience and has a keen eye for licensing opportunities, both in Canada and in international markets.Jeff Renwick, Chief Executive Officer and a Director, commented "We are grateful for the opportunity to add someone of Bob's calibre ...

  • Newsfile2 months ago

    Canntab Provides Clarification on CFN Media Engagement

    Toronto, Ontario--(Newsfile Corp. - May 15, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") wishes to provide clarification on the terms of its engagement of CFN Media Group ("CFN Media"), which were previously announced in a news release disseminated by CFN Media on May 15, 2018. Canntab wishes to clarify that CFN Media was engaged to provide investor relations services. The terms of the engagement require Canntab to pay CFN Media ...

  • GlobeNewswire2 months ago

    Canntab Therapeutics Engages CFN Media to Build New Investor Audience

    SEATTLE, May 15, 2018-- CFN Media Group, the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Canntab Therapeutics Ltd. has engaged CFN ...

  • Newsfile2 months ago

    Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

    Paris, Ontario--(Newsfile Corp. - May 14, 2018) - Emblem Corp. (TSXV: EMC) (TSXV: EMC.WT) ("Emblem" or the "Company") and Canntab Therapeutics Limited (CSE: PILL) ("Canntab") are pleased announce to receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the "Sustained Release Product" or the "Product"), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab's partnership to develop long-acting cannabis formulations. ...

  • GlobeNewswire2 months ago

    Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

    Emblem Corp. (EMC.V) (EMC-WT.V) (“Emblem” or the "Company") and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the “Sustained Release Product” or the “Product”), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab’s partnership to develop long-acting cannabis formulations. “Product innovation, new formulations and dosage forms are critical pillars in Emblem’s competitive strength and growth strategy. Our licence agreement with Canntab is an important step in this direction. “We are thrilled that Health Canada has approved the research and development phase of our partnership with Canntab.

  • Newsfile3 months ago

    CSE New Listing - Canntab Therapeutics Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - April 27, 2018) - Canntab Therapeutics (CSE: PILL) is one of the latest new listings on the Canadian Securities Exchange. Markham, Ontario-based Canntab is a Canadian cannabis oral dosage formulation company, en-gaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. InvestmentPitch Media has produced a "video" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and ...